HLS Therapeutics Inc.
TSX:HLS.TODrug Manufacturers - Specialty & Generic
-$0.11 today
- Market cap
- $116.32M
- Beta
- 0.85
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$0.33
Volume 0.04M
Average 0.01M
HLS.TO Net Income
Bottom-line profit, the starting point for calculating cash from operations.
HLS Therapeutics Inc.TSX: HLS.TO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $2.3M (cash outflow) fell 48.2% year over year, behind the -42.7% change in trailing-twelve-month net income. Sequentially, it rose 69.5% from the prior quarter. Over 3 fiscal years it compounded at -19.2% a year.
Context
- Net income amounted to 22.0% of revenue in FY2025, down 12.7 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$6.63M (-46.7%) for the fiscal year ending Dec 2026, a slowdown from the -36.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$2.3M+69.5% QoQ
- Last fiscal yearDec 2025
- -$12.43M-36.8% YoY
- LTMMar 2026
- -$10.31M-42.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -48.2% | -10.3% | +37.9 pp |
| 1 year | -36.8% | -46.7% | -9.9 pp |
| 3-year CAGR | -19.2% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (12.43M) USD
- Year-over-year change
- +36.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (12.43M) | +36.8% |
| FY2024 | 2024-12-31 | (19.66M) | +28.6% |
| FY2023 | 2023-12-31 | (27.53M) | -16.7% |
| FY2022 | 2022-12-31 | (23.6M) | -79.9% |
| FY2021 | 2021-12-31 | (13.12M) | — |
Net Income vs competitors
How HLS.TO compares with its peers on the latest reported figures
- HLS.TO's LTM Mar 2026 net income of $10.31M is the 5th largest of the 7 companies compared; the peer median is $38.15M.
- Its year-over-year change of -42.7% is the 4th highest of 6, against a peer median of +27.1%.
- Net income amounts to 18.5% of revenue for HLS.TO, versus a peer median of 10.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $108.22B | — | +109.1% | — | |
| LTM Jun 2026 | $1.1B | -2132.0% | — | 10.2% | |
| LTM Jun 2026 | $215.32M | +320.2% | — | 6.9% | |
| LTM Mar 2026 | $68.91M | +27.1% | +15.5% | 137.1% | |
| LTM Mar 2026 | $10.31M | -42.7% | -19.2% | 18.5% | |
| LTM Mar 2026 | $7.4M | +124.6% | -20.3% | 17.6% | |
| LTM Mar 2026 | $1.48M | -67.8% | -20.1% | 1.7% | |
| Peer median (excluding HLS.TO) | $38.15M | +27.1% | -2.3% | 10.2% | |
Competitors are the stored peer set for HLS.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (13.12M) | (23.6M) | (27.53M) | (19.66M) | (12.43M) |
| Depreciation & Amortization | 30.26M | 34.4M | 31.94M | 22.72M | 22.2M |
| Deferred Income Tax | 1.14M | 138K | (696K) | 3.81M | (1.3M) |
| Stock-Based Compensation | 2.35M | 2.92M | (538K) | 1.62M | 1.91M |
| Change in Working Capital | (3.02M) | 1.55M | 5.04M | 1.14M | 4.82M |
| Accounts Receivables | 1.04M | (71K) | 629K | 2.37M | 1.02K |
| Inventory | 1.77M | (622K) | (661K) | (189K) | 1.3M |
| Accounts Payables | (3.65M) | 3.24M | 1.99M | (4.3M) | 857.76K |
| Other Working Capital | (2.19M) | (999K) | 3.08M | 3.26M | 2.66M |
| Other Non-Cash Items | (1.19M) | 1.53M | 7.58M | (1.63M) | 819.78K |
| Operating Cash Flow | 16.43M | 16.94M | 15.79M | 8M | 16.02M |
| Capital Expenditures | (4.51M) | (10.15M) | (189K) | (15K) | (208.59K) |
| Acquisitions (Net) | 0 | 0 | 0 | (1.5M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (4.46M) | (10.1M) | (148K) | 13.25M | 0 |
| Investing Cash Flow | (4.51M) | (10.15M) | (189K) | 11.74M | (1.73M) |
| Debt Repayment | (11.14M) | (441K) | (9.46M) | (21.57M) | (18.07M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (47K) | (998K) | (1.55M) | (600K) | (1.83M) |
| Dividends Paid | (5.12M) | (4.96M) | (2.4M) | 0 | 0 |
| Other Financing Activities | 4.91M | (455K) | (1.23M) | (1.19M) | (624.75K) |
| Financing Cash Flow | (11.4M) | (6.86M) | (14.64M) | (23.36M) | (20.52M) |
| Effect of Forex Changes | 46K | (394K) | 268K | (870K) | (343.66K) |
| Net Change in Cash | 567K | (456K) | 1.23M | (4.5M) | (6.58M) |
| Free Cash Flow | 11.92M | 6.79M | 15.6M | 7.99M | 15.81M |
HLS Therapeutics Inc.
TSX:HLS.TO
Intrinsic Alpha fair value
Locked
Current Price
$3.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.